We are proud to present our new board member in Milmed Unico AB, Anna Linton.
Anna has over 20 years of experience from the development, commercialization and distribution of pharmaceuticals. During the last 10 years, she has been responsible for a life science company in an expansive phase. Experiences that are significant for Milmed Unico AB in our ambition to create non-toxic treatments without adverse side effects. Anna has recently joined Pharmiva as new CEO, which is a leading operator in the work for better vaginal health.
Anna most recently comes from the Unimedic Group, which develops and distributes specialist medicines and is also a contract manufacturer of medicines. Previous assignments include roles as Nordic Head of Recordati and Nordic CEO at Grünenthal, as well as leading roles in commercialization and sales at Abbot, Wyeth and Pfizer. We wish her a warm welcome to our board and look forward to a long and fruitful collaboration.
